BridgeBio Pharma

Yahoo Finance • 3 days ago

BridgeBio outlines transition to cash generation by 2028 with $600M profit target, driven by pipeline advances and Attruby growth

Earnings Call Insights: BridgeBio Pharma, Inc. (BBIO) Q4 2025 MANAGEMENT VIEW * CEO Neil Kumar described the quarter as a transformative inflection point, stating, "This company will turn from a cash consumptive business to one that ge... Full story

Yahoo Finance • 3 days ago

BridgeBio Pharma GAAP EPS of -$1.00 misses by $0.33, revenue of $154.2M beats by $5.13M

* BridgeBio Pharma press release [https://seekingalpha.com/pr/20411990-bridgebio-reports-fourth-quarter-and-full-year-2025-financial-results-and-commercial-updates] (BBIO [https://seekingalpha.com/symbol/BBIO]): Q4 GAAP EPS of -$1.00 mis... Full story

Yahoo Finance • 10 days ago

BoFA Notes BridgeBio Pharma, Inc. (BBIO)’s Upcoming Q4 Earnings May Have Limited Market Impact

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.BoFA Notes BridgeBio Pharma, Inc. (BBIO)'s Upcoming Q4 Earnings May Have Limited Market Impact BridgeBio Pharma, Inc. (NASDAQ:B... Full story

Yahoo Finance • 10 days ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on Februa... Full story

Yahoo Finance • 13 days ago

Tyra Biosciences price target raised to $53 from $37 at Wedbush

Wedbush analyst Robert Driscoll raised the firm’s price target on Tyra Biosciences (TYRA) to $53 from $37 and keeps an Outperform rating on the shares. The firm notes BridgeBio (BBIO) announced positive topline Phase 3 data for infigratini... Full story

Yahoo Finance • 15 days ago

BridgeBio rises after late-stage trial win for dwarfism therapy

[Achondroplasia] Hailshadow BridgeBio Pharma (BBIO [https://seekingalpha.com/symbol/BBIO]) added ~13% in the premarket on Thursday after the company reported success in a pivotal Phase 3 trial for infigratinib, its experimental therapy fo... Full story

Yahoo Finance • 2 months ago

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of Cormorant’s reportable 13F as... Full story

Yahoo Finance • 3 months ago

PayPal downgraded, Roku upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Jefferies upgraded Roku (ROKU) to Buy... Full story

Yahoo Finance • 3 months ago

Here Are Thursday’s Top Wall Street Analyst Research Calls: American Eagle Outfitters, Ferrari, Intuitive Surgical, Roku, PayPal, Synopsis, Visa, and More

Chaay_Tee / iStock via Getty Images Quick Read As expected, the Federal Reserve cut the Funds rate 25 basis points on Wednesday. The rate cut lowered the Fed funds rate to 3.50%-3.75%, the lowest since the post-pandemic era in 2022. Rate... Full story

Yahoo Finance • 3 months ago

BridgeBio to Participate in December Investor Conferences

PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its managemen... Full story

Yahoo Finance • 3 months ago

Alphabet’s Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too?

24/7 Wall St. Quick Read Alphabet (GOOG,GOOGL) holds a portfolio of 37 stocks worth $2.5B to $3B through its venture arms GV and CapitalG. Google’s portfolio is heavily tilted toward healthcare and biotech with its largest holding being... Full story

Yahoo Finance • 4 months ago

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to pla... Full story

Yahoo Finance • 4 months ago

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital po... Full story

Yahoo Finance • 4 months ago

Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.

Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs. Continue Reading View Comments... Full story

Yahoo Finance • 4 months ago

BridgeBio targets 30%+ market share for Attruby while advancing late-stage pipeline and reporting $120.7M Q3 revenue

Earnings Call Insights: BridgeBio Pharma (BBIO) Q3 2025 MANAGEMENT VIEW * Neil Kumar, CEO, opened the call highlighting "continued momentum, both scientifically and commercially in this franchise and are ever more confident today that... Full story

Yahoo Finance • 4 months ago

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

- $120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue - As of October 25, 2025, 5,259 unique... Full story

Yahoo Finance • 4 months ago

Here are the major earnings after the close Wednesday

Major earnings expected after the bell on Wednesday include: * Microsoft Corporation (MSFT [https://seekingalpha.com/symbol/MSFT]) * Alphabet (GOOG [https://seekingalpha.com/symbol/GOOG]) * Meta Platforms (META [https://seekingalpha... Full story

Yahoo Finance • 4 months ago

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

PALO ALTO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced plans to release topline resu... Full story

Yahoo Finance • 4 months ago

BridgeBio rises after late-stage muscular dystrophy trial success

[Double exposure microscope Young woman scientific using equipment for research. Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology] jittawit.21/iStock via Getty Images BridgeBio Pharma (NASDAQ:BBIO... Full story

Yahoo Finance • 4 months ago

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies - Primary interim analysis endpoint, glycosylated αDG, si... Full story